Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to selective GLP-1 agonists (semaglutide) and basal insulins (degludec, glargine) in patients with type 2 diabetes.
Tirzepatide is a once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1) to improve how your body handles sugar and fat. Clinical trials show it lowers blood sugar and reduces body weight more effectively than standard diabetes medications like insulin or other GLP-1 drugs like semaglutide. It is prescribed for adults with type 2 diabetes or obesity, starting at a low dose to minimize stomach upset, and increasing over time. It is not suitable for people with a specific family history of thyroid cancer.
Compared to the selective GLP-1 receptor agonist semaglutide in patients with T2DM (SURPASS-2 clinical trial), tirzepatide was superior in decreasing in a dose-dependent manner the mean glycated hemoglobin (HbA1c) levels (up to 2.3% reduction from baseline)... Furthermore, compared to insulin degludec (SURPASS-3) and insulin glargine (SURPASS-4), once-weekly tirzepatide has shown greater reductions in HbA1c and body weight with lower adverse effects including hypoglycemia.
Why this rating
Based on multiple Phase 3 randomized controlled trials (SURPASS-1 through 5, SURMOUNT-1) cited in the review.
Source
The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
Ioannis Lempesis et al. · Metabolism Open · 2022
DOI 10.1016/j.metop.2022.100220
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →